Citigroup is upgraded based on strong operating results and a somewhat improved starting valuation. Click to read more on the ...
Fintel reports that on September 30, 2026, Citigroup downgraded their outlook for Moderna, Inc. - Depositary Receipt (BASE:MRNA) from Neutral to Sell. This rating action follows a prior action by ...
A new report from the investment bank says renewed investor demand could lift crypto prices.
Citigroup raised its 12-month Bitcoin price target to $113,000 from $82,000, pointing to gradual ETF inflows and a firmer ...
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a ...
Citigroup increased its 12-month bitcoin forecast to $113,000, citing resumed ETF inflows and favorable economic conditions ...
Citigroup has reportedly hiked its 12-month forecasts for bitcoin and ether as cryptocurrency activity picks up. The ...
Selling across financial stocks is landing hardest on some of the biggest U.S. banks, and Citigroup (NYSE:C) shares are ...
Citigroup lifted its 12-month bitcoin target to $113,000 and ether to $3,028, citing returning ETF inflows and steadier macro ...
Bitcoin (BTC) Price Forecast Jumps to $113,000 as Citigroup Upgrades Target Following Record Quarter
Citigroup upgrades Bitcoin (BTC) price target to $113,000 from $82,000 after strongest quarterly gains since 2024, despite ...
Citigroup Mortgage Loan Trust 2026-HYB1 receives final Fitch ratings for its $383.48 million RMBS issuance backed by prime ...
These securities are tied to the S&P 500 Index (ticker: "SPX"), featuring a stated principal amount of $1,000 per security ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results